DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20213866

Compassionate use of remdesivir in pregnancy: a case series

Jui R. Shah, Khushali P. Parikh, Aayushi A. Suthar, Sushma R. Shah, Supriya D. Malhotra

Abstract


Coronavirus disease 2019 (COVID-19) has resulted in an unprecedented global healthcare crisis. One special population that poses a challenge is pregnant women with COVID-19. However, there is limited data on treatment options for severe coronavirus disease in pregnancy. Remdesivir, an antiviral drug, is currently being studied as a potential treatment of COVID-19 pneumonia. Nevertheless, pregnant women are also being excluded from various clinical trials for the disease. There are some studies mentioned in the literature which have shown no adverse effects of remdesivir during pregnancy. In this study, we present four serial cases of COVID-19 in pregnant women with moderate to severe symptoms who were treated with remdesivir. All of the them showed positive fetal outcome without any birth defects or malformations. However, further studies are necessary to evaluate the biosafety and effects of remdesivir in pregnant women.


Keywords


COVID-19, Remdesivir, Pregnancy, Moderate-severe symptoms

Full Text:

PDF

References


Igbinosa I, Miller S, Bianco K, Nelson J, Kappagodaet S, Blackburn BG et al. Use of remdesivir for pregnant patients with severe novel coronavirus disease 2019. Am J Obstet Gynecol. 2020;223:768-70.

Odayar J, Myer L, Malaba TR. The epidemiology and pathogenesis of SARS-CoV-2 infection in pregnancy: More questions than answers. E-Clin Med. 2020;26:100534.

Knight M, Bunch K, Vousden N, Morris E, Simpson N, Gale C et al. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population-based cohort study. BMJ. 2020;m2107.

Lampejo T. Remdesivir for the treatment of COVIDÔÇÉ19 in pregnancy. J Med Virol. 2021;93(7):4114.

Saroyo YB, Rumondang A, Febriana IS, Harzif AK, Irwinda R. Remdesivir Treatment for COVID-19 in Pregnant Patients with Moderate to Severe Symptoms: Serial Case Report. Infect Dis Rep. 2021;13:437-43.

US Food and Drug Administration. Remdesivir EUA letter of authorization. 2020. Available at: https://www.fda.gov/media/137564/download. Accessed on March 22, 2021.

National Clinical management protocol: COVID-19. 2020. Available at: https://www.mohfw.gov.in/pdf/UpdatedClinicalManagementProtocolforCOVID19dated03072020.pdf. Accessed on March 22, 2021.

Singh V, Choudhary A. Treatment with Remdesivir in Two Pregnant Patients With COVID-19 Pneumonia. Cureus. 2020;13(5):e14986.

Smith DD, Pippen JL, Adesomo AA, Rood KM, Landon MB, Costantine MM. Exclusion of pregnant women from clinical trials during the coronavirus disease 2019 pandemic: a review of international registries. Am J Perinatol. 2019;37(8):792-9.

Dande R, Qureshi A, Persaud K, Puri C, Zulfiqar S, Awasthi S. Remdesivir in a pregnant patient with COVID-19 pneumonia. J. Community Hosp Intern Med Perspect. 2021;11:103-6.

Maldarelli GA, Savage M, Mazur S, Oxford-Horrey C, Salvatore M, Marks KM. Remdesivir treatment for severe COVID-19 in third-trimester pregnancy: case report and management discussion. Open Forum Infect Dis. 2020;7(9):ofaa345.

Donner B, Niranjan V, Hoffman G. Safety of Oseltamivir in pregnancy. Rev Preclin Clin Data Drug Saf. 2010;33:631-42.